



# Protein Kinase 2012

## Signalling Success: 5th SCI-RSC symposium on kinase inhibitor design

Monday 21 - Tuesday 22 May 2012

Accelrys, Cambridge Science Park, Cambridge, UK

**RSC** | Advancing the  
Chemical Sciences

Organised by SCI's Fine Chemicals Group and the  
RSC's Biological and Medicinal Chemistry Sector in  
Partnership with Accelrys

  
**SCI**  
where science meets business

## **Monday 21 May**

- 08:30 Registration and refreshments
- 09:20 Opening remarks
- 09:30 **The ABC of kinase conformations**  
Henrik Möbitz (Novartis, Switzerland)
- 10:15 **Structure-based design for kinases guided by fragment-molecular-orbital and water analysis**  
Richard Law (Evotec, UK)
- 11:00 Refreshments
- 11:30 **Mass spectrometry based proteomics approaches for mode of action analysis of kinase inhibitors**  
Christian Eckert (Evotec, Germany)
- 12:15 **Incorporation of binding kinetics into lead optimization**  
Peter Brandt (Beactica, Sweden)
- 13:00 Lunch
- 14:00 **Non-ATP competitive kinase inhibitors: potential and limitations**  
Sandra Jacob (Novartis, Switzerland)
- 14.45 **Kinobeads™ enabled discovery of CZC54109 a highly selective and orally efficacious inhibitor of mTOR**  
Andrew Cansfield (Cellzome, UK)
- 15:15 **The design and synthesis of 6-ethynylpurines as irreversible inhibitors of Nek2 kinase**  
Christopher Matheson (Northern Institute for Cancer Research, UK)
- 15:45 Refreshments
- 16:15 Presentation of posters
- 17:00 Posters and drinks reception
- 18:00 BBQ and networking

## Tuesday 22 May

- 08:30 Refreshments
- 09:00 **Structure based design of novel allosteric MEK templates: optimising a critical H-bonding interaction**  
Robert Heald (Argenta, UK)
- 09:45 **A snapshot of kinase research at Roche Nutley:**  
**1) developing selective kinase inhibitors for inflammation targets**  
**2) kinase inhibitors for chemical biology**  
Michael Soth (Roche, US)
- 10:30 **Novel triazolopyridine compounds as selective JAK1 kinase inhibitors: from hit to clinical candidate (GLPG0634)**  
Christel Menet (Galapagos, Belgium)
- 11:15 Refreshments
- 11:45 **Using structure-based drug design to identify novel oral and inhaled p38 inhibitors for asthma and COPD**  
John Mathias (Pfizer, UK)
- 12:30 **Inhaled PI3K $\delta$  inhibitors for respiratory indications**  
Nicole Hamblin (GlaxoSmithKline, UK)
- 13:15 Lunch
- 14:15 **Discovery of AZD5363, an orally bioavailable, potent inhibitor of AKT kinases**  
Richard Luke (AstraZeneca, UK)
- 15:00 **Fragment based drug discovery of selective inhibitors of Fibroblast Growth Factor Receptor (FGFR)**  
Gordon Saxty (Astex, UK)
- 15:45 **The discovery of AZD4547: an orally bioavailable, potent and selective N-(5-pyrazolyl)benzamide FGFR1-3 inhibitor**  
Andrew Thomas (AstraZeneca, UK)
- 16:30 Concluding Remarks

## Synopsis

Confirmation of protein kinases as clinically relevant targets has been demonstrated by the success of drugs in the oncology market.

The year 2011 saw the approval of three new drugs that target various types of cancer and ongoing clinical trials suggest that there is a healthy pipeline of kinase inhibitors to follow. This symposium will detail recent progress in the area of Protein Kinases (PKs) and address the challenges and issues associated with converting kinase inhibitors into clinical compounds in oncology but also in non-oncology settings. There will be talks on how some of the latest technologies are being applied to PK inhibitor programmes to help identify the next generation of drugs that act on this family of enzymes as well as the first disclosure of some recent clinical candidates.

## Attendees

This event is aimed at all scientists interested in furthering their knowledge of kinases. It will also have wider appeal to members of the drug discovery community eager to understand how enzyme inhibitor programmes are approached and executed across the pharmaceutical industry.

Please note there are a limited number of spaces at the conference.

## Posters

A poster session will take place at the end of Day 1. A one-page abstract should be submitted to [jacqui.colgate@soci.org](mailto:jacqui.colgate@soci.org) by 31st March 2012. When submitting posters delegates should indicate whether they would be prepared to give a 1-2 slide summary of their poster in a formal presentation session that will take place on Day 1.

## Venue

Accelrys is located at 334 Cambridge Science Park, Cambridge CB4 0WN.  
Tel no: 01223 228500

## Accommodation

Please note that accommodation is not included in the registration fees and that transportation to and from the venue is not provided. Suggestions for hotels can be found at: <http://accelrys.com/about/locations/directions-cambridge.html> and there are hotels a short taxi ride or 10 minute walk from the venue. Parking is available on the Accelrys site. Spaces are limited so please ensure you reserve one if required at time of registration.

## Travel

Travel to Cambridge is convenient by road or rail. Accelrys is in the Cambridge Science Park. There are frequent train services to Cambridge from London Kings Cross and Liverpool Street Stations. The nearest international airport is London Stansted (30 miles) which has rail and coach links to Cambridge. From London Heathrow and Gatwick Airports there are express rail links to central London for onward rail journeys as above. There are also coach links from both airports direct to Cambridge.

## Organisers

Kathryn Bell (Cellzome, UK)  
Stephen East (Evotec, UK)  
Roger Griffin (University of Newcastle, UK)  
Mark Hanson (Accelrys, UK)  
John Harris (CJH Consultants, UK)  
Keith Jones (Institute of Cancer Research, UK)

Jackie Macritchie (BioFocus, UK)  
Parminder Ruprah (Takeda, UK)  
Andrew Thomas (AstraZeneca, UK)  
Adele Willacy (Accelrys, UK)

## Sponsor

Accelrys and its predecessors have been based in Cambridge since 1989. The original Cambridge operation was a startup software company that emerged from the University's Materials Science Department. The company retains close ties with the local academic and high tech community. Accelrys are located on the well known Cambridge Science Park.



## Information on RSC

The RSC is a learned society and professional body for the chemical sciences

Members of the RSC come from diverse areas of the chemical sciences and are employed in a wide variety of professions worldwide.

The Biological & Medicinal Chemistry Sector (BMCS), as part of the Industry & Technology Division, aims to further the interests of all members of the RSC, both industrial and academic, involved in the pursuit and understanding of biologically active molecules.

**Further information about the activities of the BMCS and benefits of the RSC membership can be found at [www.rsc.org/bmcs](http://www.rsc.org/bmcs)**



## Information on SCI

SCI is an international, independent charity whose remit is to promote the application of science for the benefit of society.

SCI is the publisher of many well respected journals and industry leader Chemistry & Industry magazine (C&I). SCI can offer a network of contacts spanning education, science and business, an in-depth knowledge of chemical related industries together with a rolling programme of conferences, awards and scholarships to help further knowledge and support those involved in the sector no matter what stage of their careers.

**For more information on the benefits of joining SCI please go to [www.soci.org/membership](http://www.soci.org/membership)**



